Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clostridium Difficile-Associated Diarrhea Clear all
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

NCT02218372
View directory record Official record
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Interventions
Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid, Vancomycin capsules
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
Up to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Orange, California • Chicago, Illinois • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00269399
View directory record Official record
Conditions
Clostridium Infections, Diarrhea
Interventions
Rifaximin (Xifaxan), Vancomycin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

NCT01401023
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile
Interventions
Tigecycline
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
East Lansing, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

NCT03105479
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Cadazolid, Vancomycin capsule, Vancomycin solution
Drug
Lead sponsor
Actelion
Industry
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 20, 2026, 6:16 PM EDT
Completed No phase listed Observational

Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea

NCT00304876
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

NCT00350298
View directory record Official record
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 20, 2026, 6:16 PM EDT
Withdrawn Phase 4 Interventional

Addition of Lactobacillus to Metronidazole in Treatment of CDAD

NCT00304863
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
Interventions
Lactobacillus GG
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 1 Interventional

Probiotics in the Reduction of Antibiotic Associated Diarrhea

NCT02589964
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Florajen-3, Placebo
Dietary Supplement · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 20, 2026, 6:16 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics

NCT01873872
View directory record Official record
Conditions
Development of Clostridium Difficile Associated Diarrhea
Interventions
Theralac probiotic, Culturelle probiotic, placebo
Dietary Supplement · Other
Lead sponsor
St. Vincent's East, Birmingham, Alabama
Other
Eligibility
19 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

NCT04247542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Ibezapolstat, Vancomycin
Drug
Lead sponsor
Acurx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
29
States / cities
Scottsdale, Arizona • Apple Valley, California • Camarillo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00097422
View directory record Official record
Conditions
Diarrhea
Interventions
OPT-80
Drug
Lead sponsor
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New Hope, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

NCT01222702
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Cadazolid, Vancomycin, Placebo-matching cadazolid, Placebo-matching vancomycin
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Newark, Delaware • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

NCT01925417
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection
Interventions
RBX2660 (microbiota suspension)
Biological
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

NCT01232595
View directory record Official record
Conditions
Moderate Clostridium Difficile Infection
Interventions
LFF571, Vancomycin (POC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 20, 2026, 6:16 PM EDT
Recruiting Not applicable Interventional

Fecal Microbiota Transplantation for C Diff Infection

NCT01905709
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Human fecal matter
Biological
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Phase 4 Interventional Results available

IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

NCT00177970
View directory record Official record
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Interventions
intravenous immunoglobulin G (IVIG), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Not applicable Interventional

Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile

NCT02127814
View directory record Official record
Conditions
Antibiotic-associated Diarrhea, Clostridium Difficile
Interventions
Lactobacillus reuteri
Dietary Supplement
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

NCT02092935
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SMT19969, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Mobile, Alabama • Laguna Hills, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 20, 2026, 6:16 PM EDT
Suspended Phase 4 Interventional

Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy

NCT00591357
View directory record Official record
Conditions
Antibiotic-Associated Diarrhea, Clostridium Difficile
Interventions
loperamide, placebo
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 20, 2026, 6:16 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease

NCT02076438
View directory record Official record
Conditions
Diarrhea
Interventions
Probiotics
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00468728
View directory record Official record
Conditions
Clostridium Infections, Diarrhea
Interventions
PAR-101/OPT-80, Vancomycin
Drug
Lead sponsor
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
16 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
53
States / cities
Gadsden, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea

NCT00034294
View directory record Official record
Conditions
Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile Diarrhea, Antibiotic-associated Colitis, Antibiotic-associated Diarrhea
Interventions
GT160-246
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 20, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

NCT03824795
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
MGB-BP-3
Drug
Lead sponsor
MGB Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Miami, Florida • Orlando, Florida • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 20, 2026, 6:16 PM EDT